<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129596">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117076</url>
  </required_header>
  <id_info>
    <org_study_id>RLS and Gabapentin or Horizant</org_study_id>
    <nct_id>NCT02117076</nct_id>
  </id_info>
  <brief_title>Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome</brief_title>
  <official_title>Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theresa Zesiewicz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lehigh Valley Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin)
      versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>International Restless Leg Syndrome Rating Scale (IRLS)</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restless Leg Syndrome Quality of Life Scale (RLSQoL)</measure>
    <time_frame>Baseline, day 35, day 54.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Medical Outcomes Study (MOS) Sleep Scale</measure>
    <time_frame>Baseline, day 35, day 54</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Restless Leg Syndrome</condition>
  <arm_group>
    <arm_group_label>gabapentin IR (Neurontin®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin IR is the immediate release form of the medication.  Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gabapentin enacarbil ER (Horizant™)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Horizant is the extended release form of gabapentin enacarbil.  Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin immediate release (Neurontin)</intervention_name>
    <arm_group_label>gabapentin IR (Neurontin®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin enacarbil extended release (Horizant)</intervention_name>
    <arm_group_label>gabapentin enacarbil ER (Horizant™)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients with a diagnosis of primary restless leg syndrome using the International
             Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria8.

          2. RLS symptoms ≥ 15 nights of the month prior to study enrollment and for ≥ 4 of 7
             consecutive nights in the week prior to study enrollment (if untreated).

          3. Age 18 years to 80 years.

          4. International Restless Legs Scale (IRLS) Total severity score of ≥ 15 (moderate to
             severe severity). 8

          5. Had significant sleep disturbance on item 4 of IRLS.8

          6. Women of child-bearing potential must use a reliable method of contraception.

          7. Informed consent. Subject must be willing and able to complete all study procedures.

        Exclusion Criteria:

          1. Any illness that in the investigator's opinion preclude participation in this study.

          2. Subjects with non-RLS-related sleep disorders (e.g., sleep apnea)

          3. Subjects with neurological diseases or movement disorders other than RLS (e.g.,
             diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesias, and
             dystonias)

          4. Pregnancy or lactation.

          5. Concurrent participation in another clinical study.

          6. Dementia or other psychiatric illness that prevents the patient from giving informed
             consent (Mini-Mental State Examination scores less than 27).

          7. Legal incapacity or limited legal capacity.

          8. History of RLS symptom augmentation or early-morning rebound with previous
             dopamine-agonist treatment.

          9. Clinically significant abnormalities in renal function. 3,8,10

         10. Presence of severe cardiovascular or pulmonary disease, bronchial asthma, renal,
             hepatic or endocrine disease.

         11. Concomitant treatment with drugs known to affect sleep/wake, RLS or periodic limb
             movements, including antidepressants. Subjects receiving treatment for RLS at
             screening will be required to discontinue and wash out for a minimum of 5 half-lives.

         12. Body mass index greater than 34 kg/m2.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa Zesiewicz, MD, FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J. Barbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehigh Valley Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Shaw, MPH</last_name>
    <phone>813-974-5909</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Allison, BS</last_name>
    <phone>813-974-5909</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Allison, BS</last_name>
      <phone>813-974-5909</phone>
      <email>kalliso1@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Gumulak, RN</last_name>
      <phone>610-402-9003</phone>
      <email>cheryl_D.Gumulak@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>Peter J. Barbour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Theresa Zesiewicz</investigator_full_name>
    <investigator_title>Professor of Neurology, Director USf Ataxia Center</investigator_title>
  </responsible_party>
  <keyword>Restless leg syndrome</keyword>
  <keyword>RLS</keyword>
  <keyword>gabapentin</keyword>
  <keyword>gabapentin enacarbil</keyword>
  <keyword>Neurontin</keyword>
  <keyword>Horizant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
